NeuMAX® Technology:
An Overview

 

NeuClone has world-leading expertise in the upstream development of biosimilars, including in analytics and cell biology, to confirm biosimilarity. With this experience, we have developed the NeuMAX® platform, as part of our Right from the Start® approach.

 

NeuMAX® is an integrated CHO cell-based platform for commercial- scale manufacture of complex biologics, including monoclonal antibodies and other protein drugs. The platform comprises a complementary portfolio of technologies that enhance CHO cell production of protein drugs, with major manufacturing advantages.

Neumax® Technology:
An Overview

 

NeuClone has world-leading expertise in the upstream development of biosimilars, including in analytics and cell biology, to confirm biosimilarity. With this experience, we have developed the NeuMAX® platform, as part of our Right from the Start® approach.

 

NeuMAX® is an integrated CHO cell-based platform for commercial- scale manufacture of complex biologics, including monoclonal antibodies and other protein drugs. The platform comprises a complementary portfolio of technologies that enhance CHO cell production of protein drugs, with major manufacturing advantages.

The NeuMAX® system includes:

NeuCHO®

A robust, and enhanced CHO cell line with superior viability and growth characteristics.

pNeu® -Vectors

Optimised expression vectors, designed for enhanced expression, complementary to NeuCHO® cells.

NeuGRO®

A low cost, chemically defined, and animal component-free medium formulation, designed to complement NeuCHO® cell lines.

Ellipse_background

Learn more about what we do

Download NeuClone Brochure